Lots of interesting studies in Spondyloarthritis including AxSpA and PsA at #ACR20 @RheumNow https://t.co/tIyqyMdmTf

• https://twitter.com/rheumnow/status/1325475676640645128

When discussing pregnancy outcomes with your axSpA patients, do you address potential outcomes related to disease in addition to medication concerns? #ACR20 @RheumNow

Watch my interview with Dr Sinead Maguire @Sineadm15 on her SLR and meta-analysis on pregnancy in AxSpA presented at #ACR20 abstr#1323 @rheumnow @bososhea @FionaWilsonf @tomkodwyer https://t.co/E58rhIUZA4

Adverse pregnancy outcomes risk factors in spondyloarthritis 1⃣Most common - GSA 2⃣IBD symptoms, aggressive/active disease ⬆️risk 3⃣No difference in age or steroid use Healthy mom, healthy baby. @RheumNow #ACR20 Abs#1324

Thinking of your last 20 consecutive Axial SpA patients in your clinic, which was the commonest extra-articular manifestation that you encountered? @RheumNow #ACR20 Abstr#1312

Are there distinct groups of axSpA and PsA patients with peripheral arthritis. This study shows heterogeneous patterns of peripheral involvement and overlap in SpA and PsA groups @RheumNow #ACR20 Abstr#1311 https://t.co/2Q5FH6ZrWm

Detection of inflammatory back pain (IBP) is important for the early diagnosis of Axial SpA. Which IBP criteria do you use in your clinic? @RheumNow #ACR20 Abst#1303

Pregnancy outcomes in women with AxSpA 4 prospective cohorts in Europe 328 total pregnancies Favorable outcomes overall 1⃣3% pre-eclampsia 2⃣6-9% gestational DM 3⃣0-5% preterm birth rates (similar to WHO rate 9% in Eur) @RheumNow #ACR20 Abs#1498

Exploring new mode of action for treatment of AS. In BE AGILE study, Bimekizumab (BKZ) provides further sustained long-term improvements post 48 weeks in key efficacy outcome measures to 96 weeks of treatment @RheumNow #ACR20 Abstr#1364 https://t.co/972AvDNJDq